Ophthalmology

Multimodal Ocular Imaging in Neurodegeneration

Conditions:   Alzheimer Disease;   Alzheimer Dementia;   Frontotemporal Dementia
Interventions:   Device: Spectral-Domain Optical Coherence Tomography (SD-OCT);   Device: Magnetic Resonance Imaging (MRI);   Device: Positron Emission Tomography (PET);   Diagnostic Test: Comprehensive Ophthalmic Examination;   Device: Fundus Photography
Sponsor:   University of Michigan
Not yet recruiting
ClinicalTrials.gov: Ophthalmology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

October 9, 2018 / by / in
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension – Spectrum 4 Study

Condition:   Glaucoma and Ocular Hypertension
Interventions:   Drug: DE-117 Ophthalmic Solution;   Drug: Timolol Maleate Ophthalmic Solution 0.5%
Sponsor:   Santen Inc.
Recruiting
ClinicalTrials.gov: Ophthalmology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

October 3, 2018 / by / in
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension – Spectrum 3 Study

Condition:   Glaucoma and Ocular Hypertension
Interventions:   Drug: DE-117 Ophthalmic Solution;   Drug: Timolol Maleate Ophthalmic Solution 0.5%
Sponsor:   Santen Inc.
Recruiting
ClinicalTrials.gov: Ophthalmology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

October 2, 2018 / by / in
A Phase III Study to Evaluate the Port Delivery System Implant With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway)

Condition:   Neovascular Age-Related Macular Degeneration
Interventions:   Drug: PDS Implant filled with 100 mg/mL Ranibizumab;   Drug: Intravitreal Injections of 10 mg/mL Ranibizumab
Sponsor:   Hoffmann-La Roche
Recruiting
ClinicalTrials.gov: Ophthalmology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

September 20, 2018 / by / in